Dewpoint to receive ~$55M up front, research funding & research milestones across 2 programs, ~$690M in clinical, commercial & sales milestones, and ~$107.5M in total milestones per product along with royalties across 2 commercial products, if Novo Nordisk decides other modalities for the condensates
Novo Nordisk uses Dewpoint’s discovery platform related to biomolecular condensates & identifies drug candidates. The collaboration combines Novo Nordisk’s leadership with Dewpoint’s groundbreaking discovery & AI technology platform to identify modulators of biomolecular condensates
Novo Nordisk will also discover non-small molecule drugs against identified condensates using Novo Nordisk capabilities & obtain rights to develop & commercialize potential drugs
Ref: PRNewswire | Image: Dewpoint Therapeutics
Related News:- Merck Signs an Exclusive Agreement with Dewpoint Therapeutics to Develop Curative Treatment for HIV
